medigraphic.com
ISSN 1727-897X (Electronic)

2016, Number 3

<< Back

Medisur 2016; 14 (3)

On the world sickle cell day: achivements and challenges

Fernández ÁJD

Language: Spanish
References: 17
Page: 338-340
PDF size: 74.40 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Organización Mundial de la Salud. Anemia Falciforme, 2006 [Internet]. Ginebra: OMS; 2006 [citado 3 May 2016]. Disponible en: http://apps.who.int/gb/archive/pdf_files/WHA59/A59_9-sp.pdf

  2. Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med. 1910;6:517-21

  3. Pauling L, Itano HA, Itano S, Singer J, Wells IC. Sickle cell anemia a molecular disease. Science. 1949;110(2865):543-8

  4. Neel JV. The inheritance of sickle cell anemia. Science. 1949;110(2846):64-6

  5. Beet EA. The genetics of the sickle-cell trait in a Bantu tribe. Ann Eugen. 1949;14(4):279-84

  6. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 1956;178(4537):792-4

  7. Chou ST, Fasano RM. Management of Patients with Sickle Cell Disease Using Transfusion Therapy: Guidelines and Complications. Hematol Oncol Clin North Am. 2016;30(3):591-608

  8. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-48

  9. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med. 1986;314(25):1593-9

  10. Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood. 2016;127(7):810-9

  11. Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla-Pozza L, Billings FT. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med. 1984;311(12):780-3

  12. Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database Syst Rev. 2013;5:CD007001

  13. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira E. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001;294(5550):2368-71

  14. Chandrakasan S, Malik P. Gene therapy for hemoglobinopathies: the state of the field and the future. Hematol Oncol Clin North Am. 2014;28(2):199-216

  15. Fernández Águila JD, Cabrera Zamora M, Álvarez Fernández O, Prieto Jiménez L, Mediaceja Vicente O, Villares Álvarez I. Comprehensive care for patients with sickle cell disease in Cuba. Haematologica. 2008;93:e20. doi:10.3324/haematol.11986

  16. Svarch E, Hernández P y Ballester JM. La drepanocitosis en Cuba. Rev Cubana Hematol Inmunol Hemoter [revista en Internet]. 2004 [citado 19 May 2016];20(2):[aprox. 4p]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892004000200009

  17. Machín García S, Álvarez Molina I, Svarch E, Menéndez Veitía A, Hernández Padrón C, Sosa Palacios O. Morbilidad y mortalidad de la anemia drepanocítica. Estudio observacional de 36 años. Rev Cubana Hematol Inmunol Hemoter [revista en Internet]. 2015 [citado 2 Jun 2016];31(3):[aprox. 9p]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/268




2020     |     www.medigraphic.com